BriaCell Therapeutics (TSX:BCT) Debt-to-Asset : 0.00 (As of Jan. 2024)

BriaCell Therapeutics Debt-to-Asset Chart

BriaCell Therapeutics Annual Data
	Trend	Jul14	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22	Jul23
Debt-to-Asset		Get a 7-Day Free Trial					0.73	0.78	-	-	-

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BriaCell Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, BriaCell Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Debt-to-Asset falls into.

BriaCell Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BriaCell Therapeutics's Debt-to-Asset for the fiscal year that ended in Jul. 2023 is calculated as

BriaCell Therapeutics's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics  (TSX:BCT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BriaCell Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (TSX:BCT) Business Description